- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07578675
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS (AN-CNA)
Construction of Abnormal Projection Regions of Cognitive Neural Networks in Patients With Anemia Using Functional Near-Infrared Spectroscopy (fNIRS)
Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression.
Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: ZheXiang Kuang, MSN
- Phone Number: 13920361752
- Email: kuangzhexiang@ihcams.ac.cn
Study Contact Backup
- Name: Xiao Yu, Undergraduate
- Phone Number: 18722218448
- Email: yuxiao@ihcams.ac.cn
Study Locations
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Recruiting
- Regenerative Medicine Center
-
Contact:
- Xiao Yu, Undergraduate
- Phone Number: 18722218448
- Email: yuxiao@ihcams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of anemia
- First hospitalization
- Male or female, aged 18-65 years
- Willing and able to comply with the requirements for this study and written informed consent
Exclusion Criteria:
- History of psychiatric illness
- History of severe brain disease
- Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR)
Time Frame: Patients will be assessed within 48 hours of admission.
|
Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.
|
Patients will be assessed within 48 hours of admission.
|
|
Cognitive Function Assessment
Time Frame: Patients will be assessed within 48 hours of admission.
|
Montreal Cognitive Assessment (MoCA) is used to assess cognitive function in patients, with higher total scores indicating better cognitive function.
The total score range is 0 to 30.
|
Patients will be assessed within 48 hours of admission.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety symptoms
Time Frame: Patients will be assessed within 48 hours of admission.
|
Hamilton anxiety scale(HAMA) is used to examine anxiety in AIHA patients, with higher total scores indicate more severe anxiety symptoms.
The total score range is 0-56.
|
Patients will be assessed within 48 hours of admission.
|
|
Depression symptoms
Time Frame: Patients will be assessed within 48 hours of admission.
|
Hamilton depression scale(HAMD) is used to examine depression in AIHA patients, with higher total scores indicate more severe depression symptoms.
The total score range is 0-52.
|
Patients will be assessed within 48 hours of admission.
|
|
Sleep quality
Time Frame: Patients will be assessed within 48 hours of admission.
|
The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, with a higher global score indicating poorer sleep quality.
The global score range is 0-21.
|
Patients will be assessed within 48 hours of admission.
|
|
Physical fatigue
Time Frame: Patients will be assessed within 48 hours of admission.
|
It measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale.
The total possible score is 0-52 points, with higher scores indicating less fatigue.
|
Patients will be assessed within 48 hours of admission.
|
|
Appetite condition
Time Frame: Patients will be assessed within 48 hours of admission.
|
Simplified Nutritional Appetite Questionnaire (SNAQ) is used to assess appetite in patients, with higher total scores indicating better appetite.
The total score range is 4 to 20.
|
Patients will be assessed within 48 hours of admission.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QTJC2026037
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
Bristol-Myers SquibbNot yet recruitingMyelodysplastic Syndromes (MDS)Singapore, South Korea, Taiwan
-
Institut de Recherches Internationales ServierServier Bio-Innovation LLCRecruitingMyelodysplastic Syndromes (MDS) | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)United States, France, United Kingdom, Spain, Australia, Germany, Brazil, Italy, Netherlands, Japan
-
Seug yun Yoon, MDBoryung Pharmaceutical Co., LtdNot yet recruitingAnemia | Myelodysplastic Syndromes (MDS)
-
Bristol-Myers SquibbActive, not recruitingMyelodysplastic Syndromes (MDS)United States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsActive, not recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingMyelodysplastic Syndromes, AdultChina
-
TJ Biopharma Co., Ltd.Terminated